Cabaletta Bio Inc - Asset Resilience Ratio
Cabaletta Bio Inc (CABA) has an Asset Resilience Ratio of 30.66% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CABA total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Cabaletta Bio Inc's Asset Resilience Ratio has changed over time. See CABA total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cabaletta Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cabaletta Bio Inc (CABA) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $50.62 Million | 30.66% |
| Total Liquid Assets | $50.62 Million | 30.66% |
Asset Resilience Insights
- Very High Liquidity: Cabaletta Bio Inc maintains exceptional liquid asset reserves at 30.66% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cabaletta Bio Inc Industry Peers by Asset Resilience Ratio
Compare Cabaletta Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Cabaletta Bio Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Cabaletta Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 30.66% | $50.62 Million | $165.08 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $185.05 Million | -- |
| 2023-12-31 | 18.93% | $48.01 Million | $253.65 Million | -2.39pp |
| 2022-12-31 | 21.32% | $24.94 Million | $116.97 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $126.34 Million | -- |
| 2020-12-31 | 6.30% | $7.23 Million | $114.72 Million | -- |
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immu… Read more